Document resource
Background and Importance In 2020, it was reported that piperacillin/tazobactam (PipTaz) is the second most commonly issued antibiotic in acute environments across the country. 1 Locally these doses are produced by nurses on hospital wards. With a 15-minute preparation time per dose and four daily doses per patient, this practice consumes a significant amount of nursing time.Earlier this year Regional Government published their 10-year plan,2 documenting the long-term strategy for the Healthcare Service. A pillar of this report is the innovative implementation of new technologies to transform the healthcare service.In this research we look at insourcing the manufacture of PipTaz ready to administer (RTA) doses to Pharmacy Aseptic Services utilising PipTaz multidose bags.Aim and Objectives The aim of this research was to determine whether insourcing the manufacture of RTA PipTaz doses to Pharmacy Aseptic Services could provide a sustainable solution.Material and Methods Manufacturing process development was carried out in accordance with ICH guidelines and Good Manufacturing Practice. Stability studies were carried out following the NHS Yellow Cover Document. Time in motion and production studies were carried out to obtain efficiency data.Results A semi-automated manufacturing method utilising the PipTaz multidose pack was developed. This produces a yield of 49 doses in approximately 45 minutes using 51 aseptic manipulations.The number of disposable consumables used in the process was reduced from 196 to 3.Stability for 21 days after reconstitution when stored at 5°C ±3°C.Conclusion and Relevance This research demonstrates that by utilising new technologies including the multidose PipTaz bag; Pharmacy Aseptic Services can insource the manufacture of RTA doses to help overcome downstream issues within the healthcare environment.In doing so the manufacturing process sees a reduction in manufacturing time by 81% of aseptic manipulations by 74% and in waste generation by 98% by weight.The host site prescribes an average 130,000 doses of intravenous PipTaz each year. This indicates that the sustainable insourcing of manufacturing could be an enabler of meeting the targets outlined in Governmental policy.References and/or Acknowledgements 1. Department of Health and Social Care. Transforming NHS pharmacy aseptic services in England, 2020.2. Department of Health and Social Care. Fit for Future: 10-year health plan for England, 2025.Conflict of Interest No conflict of interest